Dyadic’s C1 Platform Gains Traction in Global Health Collaborations
Event summary
- Dyadic received the final $738,743 payment from a $3.1 million Gates Foundation grant in June 2026 to support monoclonal antibody research for RSV and malaria.
- CEPI/FBS/Dyadic collaboration demonstrated plasmid-to-purified-protein production in approximately 15 days using the C1 platform.
- Dyadic expects to deliver initial purified antigen samples to Scripps Research by the end of July 2026 for Bundibugyo Ebola preparedness studies.
The big picture
Dyadic’s C1 platform is addressing a critical bottleneck in biologics manufacturing by offering faster, more scalable, and cost-efficient production of recombinant proteins and vaccines. The company’s strategic collaborations with global health organizations highlight the potential for C1 to accelerate outbreak response efforts and support commercial applications in a rapidly growing market.
What we're watching
- Platform Validation
- How the success of C1 in global health collaborations will influence its adoption in broader biopharmaceutical markets.
- Commercialization Strategy
- Whether Dyadic can effectively transition from platform validation to revenue generation through partner-funded programs and licensing agreements.
- Market Expansion
- The pace at which Dyadic can expand its commercial opportunities across the $690 billion biologics market, targeting monoclonal antibodies and other high-growth segments.
Related topics